Q-omics provides the consensus-scored NAV2-AS4 profile across patient tissues and cancer cell-line models. NAV2-AS4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NAV2-AS4 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, NAV2-AS4 RNA expression shows 16,487 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, THCA, and LSCC as cancer lineages where NAV2-AS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAV2-AS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAV2-AS4 survival associations across molecular data types. NAV2-AS4 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAV2-AS4 RNA expression–survival associations across cancer types. High NAV2-AS4 expression shows unfavorable associations in UCS, CHOL and ESCA, but favorable associations in LIHC, ACC and LGG. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UCS as the clearest survival context for NAV2-AS4 RNA expression.
This table summarizes NAV2-AS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NAV2-AS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAV2-AS4 shows lower tumor expression in THCA, KIRC, KIRP, KICH, LUSC and PRAD. The THCA box plot shows higher NAV2-AS4 RNA expression in normal versus tumor tissue (log2 FC = −0.994, t-test p < 0.001).
This table shows molecular features associated with NAV2-AS4 in patient tissues and cancer cell lines. In patient samples, NAV2-AS4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
